BPC-157 + TB-500 10mg + 10mg Regeneration

2-in-1 recovery combo.

The ultimate recovery combo. BPC-157 (local healing) plus TB-500 (systemic cell migration) in full synergy. Two complementary mechanisms in one formulation. The gold standard of advanced recovery.

59,00 €
Tax included • Free delivery from 119€
1 vial = 20 to 40 days at 250-500 mcg per day
+2,95 € cashback on this orderCreate your account: 10% off your first order and +2,95 € cashback.

Research protocols start at: 5 units, i.e. 250 mcg of each peptide per day (vial prepared with 2 ml of water).

10 mg + 10 mg = what the vial contains, not the dose.See the preparation

Minimum quantity: 11
Tax included • Free delivery from 119€
1 vial = 20 to 40 days at 250-500 mcg per day
+2,95 € cashback on this orderCreate your account: 10% off your first order and +2,95 € cashback.
68 in stockships Thursday, November 19
Subscription
53,10 €-10 %instead of 59,00 €

10% off every deliveryPause, skip or cancel in 1 clickNo commitment, no hidden fees

No automatic charge: pay for each delivery by card, in Bitcoin (an extra 5% off), or by bank transfer from €100

Worth knowing

This product contains BPC-157 et TB-500. Published work covers angiogenesis, the formation of new blood vessels. No randomised human clinical trial has characterised contraindications.

The theoretical alerts described in preclinical work concern a history of cancer, particularly vascularised solid tumours, pregnancy and breastfeeding, and proliferative retinopathies.

Your complete kit

The vial alone cannot be used as is. Add what you need to prepare it:

10mg + 10mg vialIncluded

Frequently bought together

Retatrutide
MOTS-c
MOTS-c 10mg32,00 €
GHK-Cu
GHK-Cu 100mg49,00 €
PT-141
PT-141 10mg32,00 €

Research Use Only (RUO) · Prohibited for human or veterinary use.

Key facts

The BPC-157 + TB-500 10mg + 10mg combo delivers in a single vial the two most extensively studied tissue regeneration peptides in musculoskeletal research: 10 mg of BPC-157 (Body Protection Compound-157, a 15-amino-acid pentadecapeptide derived from human gastric juice, isolated by Predrag Sikiric's team at Zagreb from the 1990s) paired with 10 mg of TB-500 (active fragment of thymosin beta-4 described by Allan Goldstein in 1981, 44-residue ubiquitous regeneration peptide). Together these molecules constitute the reference pairing in tendon, ligament, muscle and vascular repair research: two complementary mechanisms of action, one shared angiogenic vector, and dramatically expanded tissue coverage.

In detail

BPC-157 operates locally as an ultra-stable cytoprotectant: it survives gastric milieu, reactivates the VEGF-receptor-2 pathway at the lesion site, modulates the nitric oxide system (NO / eNOS), upregulates growth hormone receptors on tendon fibroblasts (Chang et al. 2011), and orchestrates the FAK-paxillin signaling cascade governing cell migration within tendon tissue. TB-500 operates systemically as a cytoskeleton remodeler: its primary function is G-actin monomer sequestration (active N-terminal Ac-Ser-Asp-Lys-Pro), its cleaved AcSDKP sequence is an autonomous angiogenic factor, it upregulates laminin-5 and matrix metalloproteinases (MMPs), and mobilizes mesenchymal progenitor cells.

The value of the combo lies in mechanistic divergence coupled with vascular convergence: BPC-157 covers local cytoprotection and the gut-tendon axis, TB-500 covers systemic cell migration and stem-cell mobilization, and both converge on the neoangiogenesis required for deep tissue regeneration. This combo is intended exclusively for RUO preclinical research and documented equine veterinary protocols (notably digital flexor tendon regeneration, well characterized in equine sports medicine).

Unique dual-lyophilized vial, two-minute reconstitution, aliquoting supported to extend functional shelf life.

Protocol and preparation

Reconstitution for this format (10 mg)Standard volumes used in laboratory settings
Water addedConcentrationReading marker
1 ml10 mg/ml10 UI = 1 mg
2 ml5 mg/ml40 UI = 2 mg

The volume of water does not change the product, only its concentration. Introduce the water slowly along the vial wall, never directly onto the lyophilisate, then swirl without shaking. Markers given on a 1 ml syringe graduated in 100 units.

  1. Asepsis

    Disinfect surfaces and stoppers (70% alcohol).

  2. Solvent

    Draw the required volume of bacteriostatic water.

  3. Introduction

    Inject gently against the vial wall (avoid direct jet on powder).

  4. Solubilization

    Roll the vial gently. Do not shake vigorously (degradation risk).

Solution storage Once reconstituted: 2-8°C (refrigerator).

Warning Theoretical tool for chemical handling. Does not constitute medical advice.

Open the dilution calculator
What is normal on arrivalThe observations that worry customers, and are not defects
  • The amount of powder looks tiny. A lyophilisate takes up a few millimetres at the bottom of the vial, sometimes just a translucent film. The stated weight is there.
  • The powder is compact, stuck to the wall or to the stopper. Transport moves the freeze-dried cake around. It changes nothing to reconstitution.
  • The vial carries no individual label. That is our standard packaging, not a downgraded vial.
  • After reconstitution, deposits or filaments appear. This is common, especially with small molecules. Let it settle and roll the vial between your palms, never shake it.
  • The parcel is plain. Nothing on the outside indicates the contents or the brand name.

What is not normal: a cracked vial, an uncrimped cap or a stopper that moves, powder that has liquefied or changed colour. In those specific cases, write to us with a photo and we take the vial back.

Reconstituting the 10mg + 10mg combo (BPC-157 10mg + TB-500 10mg)

The dual-lyophilized vial contains 20 mg total peptide (10 mg of each). Standard reconstitution:

  • Draw 2 ml of bacteriostatic water (benzyl alcohol 0.9% or 1%) into a 3 ml syringe with a 21G needle;
  • Disinfect the combo vial septum with an isopropyl wipe, let it dry for 10 seconds;
  • Inject the water slowly along the inner wall of the vial (never inject directly onto the lyophilized powder — mechanical impact denaturation risk);
  • Withdraw the syringe, roll the vial gently between your palms (never shake vigorously — disulfide bonds and tertiary structure are impact-sensitive);
  • Wait 60 to 120 seconds for full dissolution and a clear solution.
Final concentration: 5 mg/ml of each peptide (10 mg/ml total peptide), which on a 1 ml insulin syringe graduated to 100 IU translates as:
  • 5 IU = 0.05 ml = 250 mcg BPC-157 + 250 mcg TB-500
  • 10 IU = 0.1 ml = 500 mcg BPC-157 + 500 mcg TB-500
  • 20 IU = 0.2 ml = 1 mg BPC-157 + 1 mg TB-500

Reference protocols in preclinical research and RUO veterinary use

Two schemes dominate the gray literature and equine veterinary protocols:

  • Loading phase — 4 to 6 weeks: 500 mcg BPC-157 + 500 mcg TB-500 per day (10 IU), one subcutaneous injection daily. Injection site adjacent to the lesion for BPC-157 (local cytoprotection rationale), indifferent site for TB-500 (systemic action). Practical option: combined subcutaneous abdominal injection when the lesion is not accessible.
  • Maintenance phase — 4 to 8 weeks post-loading: 250 to 500 mcg of each peptide per day (5 to 10 IU); objective is consolidation of matrix remodeling and newly formed vascularization.

Routes of administration

  • Subcutaneous (SC) — Standard route, peri-umbilical adipose tissue. Rotate sites every 7 to 10 days to prevent local lipodystrophy.
  • Peri-lesional intramuscular (IM) — Documented in equine veterinary practice for tendinopathies (superficial digital flexor tendon); peptide is deposited in immediate proximity to the lesion.
  • Topical / intralesional — Rare, reserved for dermatological wound-healing protocols (TB-500).

Cycles and washouts

Typical full cycle duration8 to 14 weeks, followed by a 4 to 8 week washout. Washouts allow reassessment of clinical recovery (veterinary) or histological recovery (preclinical) before any reintroduction. No robust data documents uninterrupted chronic use beyond 6 months.

Technical data

Reconstitution
2 ml d'eau → 5 mg/ml de chaque peptide. 5 UI = 250 mcg de chaque ; 10 UI = 500 mcg de chaque.
Peptide sequence
Mélange : BPC-157 (10 mg) + TB-500 (thymosine β4) (10 mg)
Physical form
Poudre lyophilisée blanche
Recommended solubility
Eau bactériostatique, NaCl 0,9%
Storage conditions
Au réfrigérateur (+2 à +8 °C), à l'abri de la lumière. En poudre, possible au congélateur pour une conservation longue. Une fois préparé : réfrigérateur, jamais au congélateur.
Use
Research reagent, in vitro only (RUO)

Storage & handling

Storage before reconstitution (lyophilized) The sealed lyophilized combo vial must be stored between +2 and +8 C (refrigerator) in its original packaging, protected from light. Under these conditions, stability exceeds 24 documented months for BPC-157 and thymosin beta-4. Transit tolerates up to 48 hours at room temperature (<25 C) without significant degradation, but prolonged room-temperature storage is to be avoided. For very long-term storage (>12 months pre-reconstitution), an intact lyophilized vial can be stored at -20 C (standard freezer). Always avoid freeze-thaw cycles. Storage after reconstitution Once reconstituted with bacteriostatic water: - BPC-157 alone solution: confirmed stability 14 to 21 days at +4 C (refrigerator). - TB-500 alone solution: confirmed stability 21 to 28 days at +4 C. - Combo reconstituted solution: use within 14 days (combo stability is governed by the less stable peptide, BPC-157). Always store the reconstituted vial in its original box or in an opaque container to protect from UV light. Visually inspect before every use: the solution must remain clear, colorless to faintly straw-yellow, particle-free and non-turbid. Any cloudiness, precipitation or color shift (dark yellow, brown) requires immediate disposal of the vial. Aliquoting (recommended for protocols > 21 days) To preserve peptide potency by extending functional shelf life, aliquoting into sterile micro-tubes and storage at -20 C is the reference practice: - Reconstitute the full vial, draw 0.1 ml to 0.2 ml aliquots (sufficient for 1 to 2 injections) into sterile Eppendorf tubes;
  • Store at -20 C for up to 6 months (preclinical literature documents >90% HPLC recovery post-thaw);
  • Thaw one aliquot overnight at 4 C, return to room temperature just before injection;
  • Never re-freeze a thawed aliquot. Upon receipt, place immediately in refrigerator. If the package arrives at room temperature after > 72 h transit, contact customer service before use.

Mechanism of action

BPC-157 — Cytoprotective pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val)

BPC-157 is a 15-amino-acid fragment of a larger 40 kDa protein isolated from human gastric juice. Its exceptional stability (acid-pH resistance, enzymatic resistance outperforming most bioactive peptides) enables partial oral bioavailability and a systemic half-life compatible with once-daily administration. Four mechanisms are established by over 500 peer-reviewed publications from the Zagreb school (Sikiric, Seiwerth, Staresinic, Krivic) and independent laboratories:

  1. VEGF-R2 axis / local angiogenesis — BPC-157 upregulates VEGF-R2 (KDR) receptor expression on vascular endothelium at the lesion site, triggering early neoangiogenesis required for tendon and ligament repair (Sikiric 2018, successive reviews).
  2. FAK-paxillin signaling in tendon fibroblasts — Chang et al. (J Appl Physiol 2011) showed BPC-157 accelerates tendon fibroblast migration in vitro via FAK and paxillin phosphorylation, a critical pathway in focal adhesion remodeling.
  3. NO / eNOS axis modulation — BPC-157 normalizes nitric oxide production, a vascular and mucosal protective effect demonstrated in ischemia-reperfusion and gastroduodenal injury models.
  4. Growth hormone receptor upregulation — GH-R expression on tendon fibroblasts is increased, potentiating the local anabolic response to circulating IGF-1.

TB-500 — Thymosin beta-4 fragment (44 aa, Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES)

Thymosin beta-4 is the most abundant member of the beta-thymosin family in mammalian cell cytoplasm. Its primary function is G-actin sequestration — TB4 binds monomeric actin with nanomolar affinity, regulates the polymerizable actin pool, and indirectly governs cytoskeletal dynamics during cell migration, wound healing and inflammatory response. Five mechanistic axes are documented:

  1. G-actin sequestration — Primary function, essential for motility of fibroblasts, keratinocytes, endothelial cells and cardiomyocytes.
  2. Angiogenic AcSDKP generation — Prolyl oligopeptidase cleaves TB4 and releases the tetrapeptide Ac-Ser-Asp-Lys-Pro, an autonomous angiogenic factor layered on top of TB4's direct effect on endothelial migration.
  3. Laminin-5 and MMP upregulation — TB4 induces expression of matrix metalloproteinases (MMP-2, MMP-9) that remodel extracellular matrix during healing (Malinda 1999 J Invest Dermatol).
  4. Mesenchymal progenitor cell mobilization — TB4 activates cardiac epicardial progenitors (Smart 2011 Nature) and mobilizes hair follicle cutaneous stem cells.
  5. Anti-inflammation — NF-kB pathway inhibition and reduced pro-inflammatory mediator production in keratitis and colitis models.

Combo synergy — Vascular convergence, tissue divergence

Complementarity hinges on a single principleBPC-157 initiates local repair, TB-500 amplifies systemic regeneration. On angiogenesis, both peptides converge (VEGF-R2 for BPC-157, AcSDKP for TB-500) and potentiate each other — the shared denominator. On matrix remodeling they diverge: BPC-157 acts specifically on tendon fibroblast signaling, TB-500 acts transversally across all repairing tissues via actin dynamics. On the hormonal axis, BPC-157 potentiates local IGF-1 while TB-500 mobilizes stem cells — two orthogonal anabolic levers.

Studies and references

BPC-157 peer-reviewed corpus — Zagreb school and associated laboratories

The BPC-157 corpus exceeds 500 indexed publications since the 1990s, predominantly from the Pharmacology Laboratory at Zagreb Faculty of Medicine (Predrag Sikiric, Sven Seiwerth, Mario Staresinic, Tomislav Krivic, Rudolf Pevec). Foundational work established gastroduodenal cytoprotection (Sikiric 1993 onward), then extended to intestinal ischemia-reperfusion, tendon, ligament, muscle and cardiac injury models.

  • Staresinic et al. (J Orthop Res 2003) — Transverse medial collateral ligament injury in rat; systemically administered BPC-157 accelerated histological repair and biomechanical recovery.
  • Krivic et al. (2008) — Achilles tendon rupture in rat; BPC-157 improved tensile failure load and collagen fiber density at 14 days post-injury.
  • Pevec et al. (2010) — Crush muscle injury in rat; accelerated muscle regeneration with oral or intraperitoneal BPC-157.
  • Chang et al. (J Appl Physiol 2011) — Human tendon fibroblasts in vitro; BPC-157 accelerated migration and upregulated FAK-paxillin signaling.
  • Seiwerth et al. (Current Pharm Des 2014) — Review compiling the mechanisms known at that date (VEGF-R2, NO, dopamine, serotonin, GH-R).
  • Sikiric et al. (Current Neuropharm 2016, Current Med Chem 2018) — Extended reviews including the gut-brain axis, vascular repair and neuroprotection.

The absence of any large-scale randomized placebo-controlled human trial to date is the major limitation: all evidence is preclinical (rodent) or in vitro. Observational human protocols reported in gray literature reflect uncontrolled RUO or veterinary use.

Thymosin beta-4 / TB-500 corpus

Thymosin beta-4 enjoys an older corpus (Goldstein 1981 PNAS discovery) and human clinical trials in ophthalmology, dermatology and cardiology.

  • Goldstein et al. (PNAS 1981) — Initial isolation from bovine thymus, 44-aa sequence determined.
  • Malinda et al. (J Invest Dermatol 1999) — Cutaneous wound-healing model in rat; TB4 accelerated wound closure, induced laminin-5 and MMPs, stimulated keratinocyte migration.
  • Sosne et al. (Exp Eye Res 2005) — Topical TB4 in keratitis; accelerated corneal re-epithelialization, phase II corneal ulceration trials (RegeneRx).
  • Kim et al. (J Mol Cell Cardiol 2003) — Cardiac protection post-ischemia in mouse.
  • Smart et al. (Nature 2011) — TB4 activation of cardiac epicardial progenitors post-infarct, myocardial regeneration.
  • Crockford et al. (Ann NY Acad Sci 2010) — Phase II clinical trial of TB4 in acute myocardial infarction (RegeneRx).
  • Philp and Kleinman (Ann NY Acad Sci 2010) — Review of regenerative applications (cornea, skin, cardiac, cerebral ischemia).

Critical notethe product marketed as "TB-500" in the research peptide supply chain corresponds either to full-length thymosin beta-4 (44 aa) or to an N-terminal fragment concentrated on AcSDKP, depending on supplier. The HPLC certificate of analysis and molecular weight measured by mass spectrometry are the decisive criteria.

No references yet for this peptide — search PubMed for associated scientific literature.
The listed studies are provided for documentation and research purposes only. They do not constitute a therapeutic indication nor a recommendation for human use. This product is strictly for laboratory use only (RUO).

Similar peptides

Combo versus BPC-157 alone

BPC-157 alone remains the reference cytoprotective peptide for gastroduodenal protocols, ischemia-reperfusion models and local tendon repair. The combo adds the systemic dimension of thymosin beta-4: progenitor cell mobilization, generalized actin remodeling, AcSDKP angiogenic activity. For deep, multi-tissue tendon or ligament injuries, the combo covers a broader tissue spectrum than BPC-157 in isolation.

Combo versus TB-500 alone

TB-500 alone excels on cutaneous wounds, corneal regeneration and cardiac protection models. The combo adds gastrointestinal cytoprotection, fibroblast-specific FAK-paxillin signaling in tendons, and local IGF-1 / GH-R axis potentiation. On pure tendinopathies, the combo outperforms TB-500 alone in the majority of documented equine veterinary protocols.

Combo versus GHK-Cu

GHK-Cu (copper tripeptide) is oriented toward cutaneous wound healing and cosmetics, with a strong axis on dermal collagen synthesis and anti-glycation. The BPC-157+TB-500 combo is oriented toward deep tendon, ligament and visceral regeneration. The two are complementary and non-redundant: GHK-Cu for dermis and adnexae, BPC-157+TB-500 for deep structures (tendons, ligaments, muscles, gut).

Combo versus conventional pharmacology

NSAIDs (ibuprofen, diclofenac) reduce acute pain and inflammation but delay tissue repair by blocking the constructive inflammatory phase. Infiltrated corticosteroids relieve pain but accelerate long-term tendon degeneration. The BPC-157+TB-500 combo positions itself as a pro-regenerative strategy orthogonal to symptomatic anti-inflammatories, with an opposite mechanistic logic.

Frequently asked questions

What is the reference combo dose in preclinical research?
The scheme most frequently reported in gray literature and equine veterinary protocols is **500 mcg BPC-157 + 500 mcg TB-500 per day subcutaneously** for 4 to 6 weeks (loading phase), followed by 250 to 500 mcg of each peptide per day for 4 to 8 weeks (maintenance). Some preclinical rodent studies use weight-normalized doses (10 mcg/kg BPC-157). No human dose has been validated by clinical trial: strictly RUO use.
Are BPC-157 and TB-500 compatible in the same vial?
Yes. Both peptides are chemically stable side by side in bacteriostatic aqueous solution, with different isoelectric points (BPC-157 pI ~5.5; TB4 pI ~4.8) but no documented peptide-peptide interaction. Reconstituted combo stability is governed by the less stable peptide (BPC-157, 14 days at +4 C).
Should BPC-157 be injected near the lesion and TB-500 distally?
In theory yes: BPC-157 follows a local cytoprotection logic (VEGF-R2, FAK-paxillin) that favors peri-lesional injection when the area is accessible, while TB-500 acts systemically and can be injected at an indifferent site (abdomen). In practice with a reconstituted combo, both peptides are co-injected and the theoretical benefit of separate administration has not been demonstrated by comparative data. The equine veterinary consensus is **single peri-tendinous injection** to simplify the protocol.
Can the combo be stacked with other peptides (IGF-1, GHK-Cu, CJC/Ipamorelin)?
In preclinical research, BPC-157+TB-500 stacks with a growth hormone secretagogue (CJC-1295 + Ipamorelin) or with GHK-Cu (for skin) are documented in gray literature. Mechanisms are orthogonal: no known pharmacokinetic interaction, expected anabolic potentiation via the IGF-1 axis. These combinations remain RUO and are not supported by any comparative human clinical trial.
How long does a full cycle last and what washout should be respected?
A typical cycle lasts **8 to 14 weeks** (4 to 6 weeks loading + 4 to 8 weeks maintenance), followed by a **4 to 8 week washout**. The washout allows assessment of histological (preclinical) or clinical (veterinary) recovery before any reintroduction. No robust data documents safety of uninterrupted chronic use beyond 6 months.
What is the difference between TB-500 and full thymosin beta-4?
**Thymosin beta-4** (TB4) is the complete endogenous 44-residue molecule. **"TB-500"** as marketed in the research peptide supply chain refers, depending on supplier, either to full TB4 or to an N-terminal fragment concentrated on the active AcSDKP sequence (angiogenic tetrapeptide). Only the lot's HPLC CoA + mass spectrometry resolves the ambiguity. Our vials explicitly declare the supplied molecule on the certificate.
Is this combo usable in equine veterinary medicine?
Yes, this is in fact the best-documented use context outside of preclinical rodent research. **Superficial digital flexor tendon tendinopathies** in racehorses are the subject of reported observational veterinary protocols. Use remains under the responsibility of the attending veterinarian, within the regulatory framework applicable to research peptides (RUO) and veterinary medicinal products in the relevant jurisdiction.
What are the known contraindications and warning signs?
No randomized human clinical trial has characterized contraindications. In preclinical and veterinary settings, theoretical alerts concern: (1) **history of active cancer**, particularly vascularized solid tumors, because the angiogenic effects of BPC-157 (VEGF-R2) and TB-500 (AcSDKP) could theoretically favor tumor vascularization; (2) **pregnancy and breastfeeding** — no data, to be avoided; (3) **proliferative retinopathies** — neoangiogenesis could worsen disease. In research, any observation of abnormal bleeding, abdominal pain, cutaneous lesion change or unusual symptom should prompt discontinuation and medical evaluation.
TB-500 and Thymosin β-4: comprehensive guide to tissue regeneration researchThe complete guideTB-500 and Thymosin β-4: comprehensive guide to tissue regeneration researchTB-500 is a synthetic thymosin β-4 fragment widely studied for its effects on angiogenesis, cell migration and wound healing. Comprehensive guide: structure, mechanisms, experimental models, pharmacokinetics and research protocols.Read the guide

Also read:Solid-phase peptide synthesis (SPPS): complete guide to Merrifield, Fmoc, Boc, resins, coupling reagents and quality controlPeptide analytics: high-resolution LC-MS, NMR, HPLC and Edman - Complete research guide

Tissue repair

Regeneration

BPC-157 + TB-500: the repair duo, combined in a single vial, for tendon and joint research.

Explore the range